Lundbeck bags a PhII Parkinson's drug with $1.1B Prexton buyout deal
Six years after a team of glutamate receptor specialists spun out of the wreckage left behind by Merck KGaA’s retreat from Geneva and launched Prexton …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
